Related Experiment Videos
Buspirone augmentation of fluoxetine in obsessive-compulsive disorder
P J Markovitz1, S J Stagno, J R Calabrese
1Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH.
The American Journal of Psychiatry
|June 1, 1990
Abstract:
Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.